Human Genome Epidemiology Literature Finder
|
Records 1 - 5 (of 5 Records) |
| Query Trace: Recurrence and UGT1A1[original query] |
|---|
| Clinical implications of UGT1A1*28 genotype testing in colorectal cancer patients. Cancer 2011 Jul 117 (14): 3156-62. Shulman Katerina, Cohen Ilana, Barnett-Griness Ofra, Kuten Abraham, Gruber Stephen B, Lejbkowicz Flavio, Rennert G |
| Phase II Drug-Metabolizing Polymorphisms and Smoking Predict Recurrence of Non-Muscle-Invasive Bladder Cancer: A Gene-Smoking Interaction. Cancer prevention research (Philadelphia, Pa.) 2015 Dec . Lacombe Louis, Fradet Vincent, Levesque Eric, Pouliot Frederic, Larue Hélène, Bergeron Alain, Hovington Hélène, Caron André, Nguile-Makao Molière, Harvey Mario, Fradet Yves, Guillemette Chant |
| UGT1A1 polymorphism as a prognostic indicator of stage I ovarian clear cell carcinoma patients treated with irinotecan. Japanese journal of clinical oncology 2017 Feb 47 (2): 170-174. Yoshihama Tomoko, Hirasawa Akira, Nomura Hiroyuki, Akahane Tomoko, Nanki Yoshiko, Yamagami Wataru, Kataoka Fumio, Tominaga Eiichiro, Susumu Nobuyuki, Mushiroda Taisei, Aoki Daisu |
| UGT1A1 polymorphism has a prognostic effect in patients with stage IB or II uterine cervical cancer and one or no metastatic pelvic nodes receiving irinotecan chemotherapy: a retrospective study. BMC cancer 2020 Aug 20 (1): 729. Matsuoka Hideki, Murakami Ryusuke, Abiko Kaoru, Yamaguchi Ken, Horie Akihito, Hamanishi Junzo, Baba Tsukasa, Mandai Masa |
| Irinotecan monotherapy as third- or further-line treatment for patients with small cell lung cancer. Tumori 2021 12 107 (6): 536-541. Seto Zenta, Takata Naoki, Murayama Nozomu, Tokui Kotaro, Okazawa Seisuke, Kambara Kenta, Imanishi Shingo, Miwa Toshiro, Hayashi Ryuji, Matsui Shoko, Inomata Minehi |
- Page last reviewed:Feb 1, 2024
- Content source: